Mersana Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Martin H. Huber
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 840 Memorial Drive Cambridge MA United States of America 02139
- IPO Date
- Jun 28, 2017
- CIK
- 0001442836
- Website
- mersana.com
- Similar Companies
- Business
- Mersana Therapeutics, Inc. (Nasdaq: MRSN) is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibody-drug conjugates (ADCs) for patients with cancer and high unmet medical needs. The company leverages its proprietary Dolasynthen platform, which delivers cytotoxic auristatin payloads, and Immunosynthen platform, which delivers stimulator of interferon genes (STING) agonist immunostimulatory payloads, to create customized ADCs with improved efficacy and tolerability over first-generation technologies. Its pipeline includes lead product candidate Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4 for indications such as triple-negative breast cancer and adenoid cystic carcinoma; XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope; and preclinical candidates XMT-2068 and XMT-2175. Mersana Therapeutics maintains strategic research and development collaborations with partners including Janssen Biotech, Inc. (Johnson & Johnson) on Dolasynthen ADCs, Merck KGaA, Darmstadt, Germany on Immunosynthen ADCs, GSK plc, which holds an exclusive global license option for XMT-2056, and Ares Trading S.A. and Asana Biosciences, LLC. In November 2025, Mersana Therapeutics entered into a definitive merger agreement to be acquired by Day One Biopharmaceuticals, Inc. through a tender offer followed by a second-step merger, providing upfront cash consideration of $25.00 per share plus contingent value rights (CVRs) potentially worth up to $30.25 per share tied to clinical, regulatory, and commercial milestones for Emi-Le and certain collaboration milestones, for a total equity value of approximately $129 million at closing and up to $285 million overall; closing is expected by the end of January 2026, subject to customary conditions including majority shareholder tender and regulatory approvals. Recent milestones include FDA Fast Track designations for Emi-Le in HER2 low/negative and previously treated topoisomerase-1 inhibitor metastatic breast cancers in January 2025; $15 million development milestone payments received from GSK in July and September 2025; and U.S. FDA clearance in Q3 2025 of an investigational new drug application for a Dolasynthen ADC under the Johnson & Johnson collaboration, triggering an $8 million milestone. Founded in 2001 and headquartered in Cambridge, Massachusetts, Mersana Therapeutics operates primarily in the United States within the biotechnology sector, targeting oncology markets with a focus on solid tumors; the company, formerly known as Nanopharma Corp. until November 2005, had approximately 102 employees as of mid-2025.
Cwm LLC Cuts Stock Holdings in Mersana Therapeutics, Inc. $MRSN
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)
Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript